-- BriaCell Therapeutics（BCT.TO）週三宣布，其下一代細胞免疫療法Bria-BRES+已獲得美國食品藥物管理局（FDA）批准，可啟動針對轉移性乳癌的臨床評估。 該公司致力於開發新型免疫療法，並表示FDA批准其研究性新藥（IND）申請，標誌著Bria-BRES+的1/2a期臨床研究正式啟動。 Bria-BRES+添加了額外的免疫活化成分，旨在提升臨床療效。 Bria-BRES+基於Bria-OTS乳癌臨床項目，該項目首例接受Bria-BRES+治療的患者實現了肺轉移灶的持續完全消退。聲明指出，該患者接受了17次療程的Bria-OTS治療，完成了12個月的研究，目前仍在接受存活追蹤。 「我們很榮幸地宣布，FDA批准了我們下一代個人化免疫療法Bria-BRES+的首個IND申請，」執行長William Williams表示。 「Bria-BRES+ 的獨特設計使其在轉移性乳癌治療中展現出良好的安全性和顯著的療效。我們期待推進 Bria-BRES+ 的臨床試驗，為這些幾乎沒有有效治療選擇的患者帶來新的希望。” BriaCell 股票在紐約交易中最新報下跌 0.02 美元，至 4.05 美元。
Related Articles
Mining & Metals
Copper Lake Resources to Launch 20-For-1 Reverse Stock Split
Copper Lake Resources (CPL.V) intends to consolidate its common shares on the basis of 20 pre-consolidation common shares for every one post-consolidation common share effective as of May 8, it said Wednesday.The company currently has 271-million common shares issued and outstanding, and following the consolidation, the company will have about 13.6-million common shares issued and outstanding, prior to rounding for fractional shares.Its outstanding options of 19.5-million and warrants of 15.9-million will also be adjusted on the same basis as the common shares with proportionate adjustments being made to exercise prices.Shares of the company were last seen unchanged at $0.02 on the TSX Venture Exchange.
$CPL.V
Sectors
US Total Crude Oil Stocks Fall in Week Ended May 1
US crude oil stocks, including those in the Strategic Petroleum Reserve, fell by 7.5 million barrels in the week ended May 1 following a decrease of 13.4 million barrels in the previous week.Excluding inventories in the SPR, commercial crude oil stocks decreased by 2.3 million barrels after a 6.2-million-barrel drop in the previous week, compared with the 3.4-million-barrel decrease expected in a survey compiled by Bloomberg as of 7:35 am ET.Stocks in the SPR declined by 5.2 million in the week after falling by 7.1 million in the previous week.Overall crude oil stocks were down 0.9% from the previous week but were still up 1.5% from a year earlier. Crude oil inventories are about 1% above the five-year average for this time of year.Gasoline stocks declined by 2.5 million barrels, compared with the 2.6-million-barrel decrease expected. Gasoline stocks edged lower by 1.1% from the previous week and 2.6% from a year earlier.Distillate stocks dropped by 1.3 million barrels in the current week, compared with an expected decrease of 2.3 million barrels. Distillate stocks were down 1.2% from the previous week and 4.1% lower than in the same week a year ago.Refineries operated at 90.1% of their capacity, up from 89.6% in the previous week.
Research
Research Alert: L: Q1 Revenue And Eps Miss, Though Results May Not Be Comparable To Consensus
CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:L's Q1 revenue of CAD14.4B (+4% Y/Y) missed consensus by CAD90M, while adjusted EPS of CAD0.49 (+9% Y/Y) fell short of CAD0.52 estimates, though we think PC Financial's presentation in discontinued operations may affect comparability. Food retail same-store sales of 2.4% accelerated from Q4's 1.5%, with drug retail posting 4.1% growth. We view the solid same-store sales momentum as encouraging, particularly given internal food inflation remained well below the 4.4% CPI, indicating L's strong value proposition. Management reiterated 2026 guidance for high single-digit EPS growth and CAD2.4B in gross capex. Store expansion accelerated with 13 net openings, including five hard discount locations, aligning with consumer preference shifts toward value formats. Strong FCF of CAD621M (+189% Y/Y) supported aggressive share repurchases of CAD648M. We believe the pending PC Financial divestiture in Q3 2026 will simplify operations and provide additional capital flexibility for core retail growth.
$L